摘要
目的评价左氧氟沙星联合哌拉西林/他唑巴坦治疗呼吸机相关性肺炎(VAP)的有效性和安全性。方法分析左氧氟沙星联合哌拉西林/他唑巴坦治疗98例VAP的临床疗效;临床疗效评价分为痊愈、显效、无效,痊愈和显效的病例合计为有效。结果痊愈46例(46.9%),显效28例(28.6%),无效24例(24.5%),临床总有效率为75.5%;细菌培养共获89株病原菌,以革兰阴性菌为主,占77.5%,细菌清除率为76.4%;不良反应发生率为5.1%,主要为3例皮疹、胸闷、注射部位局部疼痛、排便次数增加;实验室检查异常2例为肝功能损害、血嗜酸粒细胞增多,均系轻度,呈一过性改变,对症处理或停药后恢复正常。结论左氧氟沙星联合哌拉西林/他唑巴坦治疗VAP,临床疗效确切、安全性高,可作为治疗VAP的经验性用药。
OBJECTIVE To evaluate the efficacy and safety of levofloxacin combined with piperacillin/tazobactam on the patients with ventilator-associated pneumonia （VAP）. METHODS The clinical effect of Levofloxacin combined with piperacillin/tazobactam on ventilator-associated pneumonia in 98 paitiens with VAP were retrospectively analyzed. RESULTS Totally 46 patients（46. 9 %） were cured, 28 patients （28. 6 % ） were markablely improved, and 24 patients（24.5% ） were ineffective. The total clinical efficacy rate was 75.5%. 89 strains of bacteria were isolated, and Gram-negative bacilli were the dominant pathogens（77. 5% ）. The bacterial clearance rate was 76.4%. The prevalence of adverse reaction was 5.1%, in which 3 cases had clinical significance （rash, dyspnea, injection site pain and diarrhea, respectively） and 2 cases had abnormal laboratory findings （ hepatic dysfuction, eosinophilia and so on）. All events were mild and transient. CONCLUSION Levofloxacin combined with piperacillin/tazobactam is effective and safe for patients with VAP.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2011年第4期775-777,共3页
Chinese Journal of Nosocomiology
